Edgewise Therapeutics (EWTX) Other Accumulated Expenses (2020 - 2026)

Edgewise Therapeutics has reported Other Accumulated Expenses for 7 years, with the latest figure at $1.2 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 14.34% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 14.34% YoY) and the FY2025 annual result came in at $759000.0, up 2.43% from the prior year.
• Other Accumulated Expenses rose to $1.2 million in Q1 2026 per EWTX's latest filing, from $759000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $1.2 million in Q1 2026 and troughed at $399000.0 in Q4 2023.
• A 5-year average of $830529.4 and a median of $804000.0 in 2022 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses soared 235.77% in 2022, then plunged 62.29% in 2023.
• Over 5 years, Other Accumulated Expenses stood at $1.1 million in 2022, then tumbled by 62.29% to $399000.0 in 2023, then jumped by 85.71% to $741000.0 in 2024, then grew by 2.43% to $759000.0 in 2025, then surged by 56.52% to $1.2 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $1.2 million, $759000.0, and $714000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.